Sun Pharma, Eicher Motors, Max Healthcare, Aurobindo Pharma, Info Edge, LTM: Target prices
MOFSL issued stock-specific calls for Sun Pharma, Max Healthcare, Eicher Motors, Aurobindo Pharma, Info Edge and LTM. It rated Sun Pharma, Max Healthcare, Aurobindo Pharma and LTM “Buy” with targets of Rs 2,210, Rs 1,200, Rs 1,200 and Rs 5,400; Eicher Motors and Info Edge “Neutral” with targets of Rs 6,912 and Rs 1,050. Key points: Sun Pharma’s Q4FY26 revenue was in-line but EBITDA/PAT missed; LTM’s Europe/Australia acquisition adds $500m annual revenue; others cited Q4 profitability drivers and
How this was made
The 30-second read
Why it matters
This is primarily a sell-side rating/target update: it can drive short-term flows, but the magnitude depends on how the market weighs near-term misses vs longer-term growth narratives.
Market read
Trading relevance is driven by explicit Buy/Neutral stances and concrete catalysts (USFDA filings, bed additions, EU growth, and LTM’s M&A).
What to watch
Broker targets rely on execution and macro stabilization; for LTM, Europe macro weakness and client insourcing/GCC trends could delay revenue stabilization despite the added deal base.
Background
The article summarizes MOFSL’s individual coverage reports and target prices across several Indian listed stocks, focusing on recent quarter results and forward catalysts.
Ticker impact
MOFSL kept Eicher Motors at Neutral after 4QFY26 profit was largely in line, with margins expected to stay under pressure from input costs.
Limited upside bias; downside risk capped given “fairly valued” framing.
Neutral rating and “fairly valued” multiples suggest muted reaction unless new margin/cost developments emerge.
Market effects
Positive read-through for pharma/healthcare sentiment (SUN, MAXHEALTH, AUROPHARMA) via pipeline execution and capacity expansion; IT services sentiment supported by LTM’s Europe/Australia deal.
India large/mid-cap coverage stocks may see rotation within domestic brokerage baskets rather than broad macro impact.
LTM’s Europe/Australia acquisition links Indian IT services growth expectations to offshore/nearshore demand and macro conditions in Europe.
Counterpoint
Buy-rated names could underperform if investors anchor on the cited Q4 earnings misses (SUN, MAXHEALTH, AUROPHARMA) or if US generics price erosion accelerates faster than assumed.
Key entities
- brokerageMOFSL
Issued Buy/Neutral calls and target prices based on Q4 results and forward growth assumptions.
- acquisition_targetRandstad technology services business
Randstad’s tech services business in Europe and Australia acquired by LTM, adding annual revenue and employees.
